Keynatinib in Treated Patients With NSCLC and Brain Metastases

NCT04824079 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer With EGFR Mutation
Brain Metastases

Interventions

DRUG: Keynatinib

Sponsor

Medolution Ltd.